Multicenter study of the performance of NTM Elite agar for the detection of nontuberculous mycobacteria from patients with cystic fibrosis

被引:1
|
作者
Andre, Emmanuel [1 ,2 ]
Lorent, Natalie [3 ]
Beuselinck, Kurt [1 ]
Deiwick, Susanne [4 ]
Dupont, Lieven [3 ]
Gafsi, Johanne [5 ]
Laenen, Lies [1 ,2 ]
Raymaekers, Lise [1 ]
Van Bleyenbergh, Pascal [3 ]
Perry, John D. [6 ]
Kahl, Barbara C. [4 ]
机构
[1] UZ Leuven Univ Hosp, Lab Med Dept, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Clin Microbiol, Leuven, Belgium
[3] Univ Hosp Leuven, Resp Dis Dept, Leuven, Belgium
[4] Univ Hosp Munster, Inst Med Microbiol, Munster, Germany
[5] BioMerieux Global Clin Affairs, Marcy Letoile, France
[6] Freeman Rd Hosp, Microbiol Dept, Newcastle Upon Tyne, England
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 10期
关键词
nontuberculous mycobacteria; cystic fibrosis; mycobacterial culture; RAPIDLY-GROWING MYCOBACTERIA; PULMONARY-DISEASE; PREVALENCE;
D O I
10.1128/spectrum.02736-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The performance of a novel selective agar was evaluated against the performance of conventional mycobacterial cultures, i.e., a combination of the mycobacterial growth indicator tube (MGIT) with L & ouml;wenstein-Jensen (LJ), for the detection of nontuberculous mycobacteria (NTM) in sputum samples from people with cystic fibrosis (pwCF). Two hundred eighty-three sputum samples (231 fresh sputum and 52 spiked sputum) from 143 pwCF were collected. They were inoculated without prior decontamination on NTM Elite agar (30 degrees C +/- 2 degrees C for 28 days) and inoculated on both MGIT and LJ (35 degrees C-37 degrees C for 6-8 weeks) after N-acetyl-L-cysteine-2% sodium hydroxide decontamination. NTM were identified by Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectrometry and/or PCR, and whole-genome sequencing. A total of 67 NTM were recovered overall by the combination of all culture media. NTM Elite agar allowed the recovery of 65 NTM (97%), compared to 22 for the conventional MGIT and LJ media combination (32.8%), including 22 NTM for MGIT (32.8%) and 3 NTM with the LJ medium (4.5%). For Mycobacterium abscessus complex, the sensitivity of NTM Elite agar was 95% compared with a sensitivity of 30% for the conventional MGIT and LJ media combination. Overall, 17.3% of cultures on NTM Elite agar were contaminated with other micro-organisms vs 46.3% on MGIT and 77% on LJ. This study shows that the novel selective agar (NTM Elite agar) significantly outperforms the conventional MGIT and LJ media combination in terms of sensitivity, selectivity, and ease of culture, without the requirement of an L3 laboratory.IMPORTANCENontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium. Nontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Clinical Evaluation of Nontuberculous Mycobacteria (NTM) Elite Agar, a New Medium for the Isolation of NTM: a Multicenter Study
    Broncano-Lavado, Antonio
    Barrado, Laura
    Lopez-Roa, Paula
    Cacho, Juana
    Domingo, Diego
    Hernandez, Sara
    Garcia-Martinez, Jesus
    Millan, Maria Rosario
    Perez-Cecilia, Elisa
    Ruiz-Serrano, Maria-Jesus
    Salso, Santiago
    Simon, Maria
    Tato, Marta
    Toro, Carlos
    Valverde-Canovas, Jose F. F.
    Esteban, Jaime
    JOURNAL OF CLINICAL MICROBIOLOGY, 2023, 61 (04)
  • [2] Nontuberculous mycobacteria I: Multicenter prevalence study in cystic fibrosis
    Olivier, KN
    Weber, DJ
    Wallace, RJ
    Faiz, AR
    Lee, JH
    Zhang, YS
    Brown-Elliot, BA
    Handler, A
    Wilson, RW
    Schechter, MS
    Edwards, LJ
    Chakraborti, S
    Knowles, MR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 828 - 834
  • [3] Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF)
    Viviani, Laura
    Harrison, Michael J.
    Zolin, Anna
    Haworth, Charles S.
    Floto, R. Andres
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (05) : 619 - 623
  • [4] Helping Map the Taxonomical Position of the Nontuberculous Mycobacteria (NTM) in Cystic Fibrosis
    Moore, John Edmund
    Millar, Beverley Cherie
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2022, 11 (03) : 303 - 308
  • [5] Multicenter Study of Prevalence of Nontuberculous Mycobacteria in Patients with Cystic Fibrosis in France
    Roux, Anne-Laure
    Catherinot, Emilie
    Ripoll, Fabienne
    Soismier, Nathalie
    Macheras, Edouard
    Ravilly, Sophie
    Bellis, Gil
    Vibet, Marie-Anne
    Le Roux, Evelyne
    Lemonnier, Lydie
    Gutierrez, Cristina
    Vincent, Veronique
    Fauroux, Brigitte
    Rottman, Martin
    Guillemot, Didier
    Gaillard, Jean-Louis
    Herrmann, Jean-Louis
    JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (12) : 4124 - 4128
  • [6] Nontuberculous Mycobacteria in Patients with Cystic Fibrosis
    Leung, Janice M.
    Olivier, Kenneth N.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 34 (01) : 124 - 134
  • [7] Nontuberculous mycobacteria in patients with cystic fibrosis
    Girón, RM
    Domingo, D
    Buendía, B
    Antón, E
    Ruiz-Velasco, LM
    Ancochea, J
    ARCHIVOS DE BRONCONEUMOLOGIA, 2005, 41 (10): : 560 - 565
  • [8] Nontuberculous mycobacteria in patients with cystic fibrosis.
    Segal, E
    Diez, GS
    Prokopio, E
    Aguirre, A
    Poggio, G
    Chertkoff, L
    MEDICINA-BUENOS AIRES, 1998, 58 (03) : 257 - 261
  • [9] Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study
    Isolina Campos-Herrero, Ma
    Javier Chamizo, Francisco
    Antonio Caminero, Jose
    Gilarranz, Raul
    Cabrera, Gonzalo
    Cuyas, Jose
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (7-8) : 526 - 531
  • [10] An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation
    Stephenson, D.
    Perry, A.
    Appleby, M. R.
    Lee, D.
    Davison, J.
    Johnston, A.
    Jones, A. L.
    Nelson, A.
    Bourke, S. J.
    Thomas, M. F.
    De Soyza, A.
    Lordan, J. L.
    Lumb, J.
    Robb, A. E.
    Samuel, J. R.
    Walton, K. E.
    Perry, J. D.
    BMC PULMONARY MEDICINE, 2019, 19 (1)